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Introduction 1 
Gastroesophageal reflux disease (GERD) is primarily determined by 
its high prevalence and the continuing increase in morbidity. GERD 
was recognized as an independent disease in October 1997 (Genval, 
Belgium). GERD is one of the most common diseases of digestive 
system which may cause such complications as esophagitis, 
esophageal strictures, ulcers, perforation, bleeding, Barrett's 
esophagus, esophageal adenocarcinoma.  
Introduction 2 
 
Over the past three decades the incidence of GERD and 
esophageal adenocarcinoma, as well as mortality from the 
latter, have increased markedly. In some regions, the incidence 
of GERD has reached almost epidemiological levels which is 
accompanied by a corresponding increase in the incidence of 
Barrett's esophagus. 
 

Our Patient 
 
 
 Name: EI 
 Gender: male 
 Age: 42 
 Occupation: office manager 
 Admitted to the hospital: 21.03.2018 
 
Complaints 
  Heartburn 
  Sour belching 
  Aggravated in a horizontal position and leaning forward after 
eating 
Anamnesis Morbi  
 Symptoms appeared approximately three months ago, for no 
reason, patient was not previously examined, did not take drugs.  
 
 Smokes 8-10 cigarettes a day. 
 
 Consumes alcohol in minimal quantities. 
Physical Examination 
Patient condition is relatively satisfactory.  
 BMI - 32 kg / m2.  
 Skin: Clean, normal color.  
 Lungs: Vesicular breathing, no wheezing 
 Heart: Muffled heart sounds, regular rhythm, no murmurs.  
 HR - 72 beats per minute, blood pressure - 120/78 mm Hg.  
 Abdomen: Soft, painless to palpation. Liver and spleen are not 
palpable.  
 The sign of tapping on the lumbar area is negative. 
 Defecation and urination are normal.  
 Laboratory  test results are within normal ranges.  
 ECG:  sinus rhythm, HR 72 beats per minute, horizontal position of 
electric axis of heart, as a variant of norm.  
 
 
 Esophagogastroduodenoscopy (EGDS): multiple areas of 
hyperemia of mucous membrane and separate non-eroding 
erosions of distal part of esophagus up to 5 mm in diameter. 
 
 
Diagnosis  
 On the basis of the patient's complaints of sour belching, aggravated in 
a horizontal position  and by leaning forward after eating the preliminary 
clinical diagnosis of “gastroesophageal reflux disease” was made.  
 
 The diagnosis of  “erosive-ulcerative reflux esophagitis” was made on 
the basis of  EGDS data (the presence of multiple areas of mucosal 
hyperemia and separate non-eroding distal esophageal erosions).  
 
The diagnosis of "obesity" was  based on inspection data (the presence 
of a BMI of more than 30 kg / m2), stage 1 of obesity corresponds to  the 
value of BMI of 32 kg / m2. 
Clinical diagnosis 
  
 
 Main diagnosis: Gastroesophageal reflux disease.  
                              Erosive-ulcerative reflux esophagitis. 
 
 
 Concomitant disease: Obesity  grade 1. 
 
Management  
We recommend 24-hour intra-esophageal pH-metry to determine the 
number and duration of reflux episodes per day, pH value; 
 
 X-ray examination of the esophagus, stomach to identify possible 
pathological changes in the esophagus, hernia of the esophageal hiatus 
of the diaphragm;  
 
Tests for determining the presence of Helicobacter pylori (HP);  
 
Manometric study of esophageal sphincters to determine their tone.  
Our Recommendation 1 
• Life style modification : 
 
 Smoking cessation  
 Weight loss 
 Diet: Patient should exclude large amounts of food, take it at a fast pace, eat 
food with a low fat content and high protein content, avoid taking foods that 
cause irritant effect on the gastric mucosa 
 
Our Recommendation 2 
Drug treatment : 
 Antacid (e.g. Aluminum phosphate): to prevent irritation of 
esophageal mucosa by acid reflux and fast heartburn relief;   
 Proton pump inhibitor (omeprazol 20 mg/day): to suppress the 
synthesis of hydrochloric acid and a  prokinetic agent to stimulate 
the motility of the gastrointestinal tract, restore the normal 
physiological condition of the esophagus (e.g. Itopride hydrochloride 
50 mg 3 times per day)). 
 In case of positive HP test result standard triple 14-days therapy for 
HP eradication (Maastricht-3) should be prescribed. 
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